Allogeneic Stem Cell Transplant

The immune effect that occurs after allogeneic stem cell transplant (“Mini-Transplant” or “Allogeneic Stem Cell Transplant”) has been described as the most powerful anti-tumor mechanism ever discovered. This mechanism is known as the “graft vs. tumor” effect or “GVT”. The GVT effect is the only mechanism known which is capable of killing or debulking chemotherapy-resistant metastatic disease. However, the clinical application of the GVT effect is severely limited due to an often lethal side-effect called “graft vs. host disease” or “GVHD”.

The detrimental GVHD effect is intimately associated with the GVT mechanism. Anything that decreases GVHD toxicity, proportionally suppresses the beneficial GVT effect. Similarly, anything that increases the GVT effect also increases the GVHD toxic effect. The separation of the beneficial GVT effect from the detrimental GVHD effect has been described as the “holy grail” of transplantation research. The “Mirror EffectTM” technology is a patented method for preserving GVT-like effects without GVHD toxicity.

The GVT effect of allogeneic transplant can kill chemotherapy-resistant cancer. In the CT scan on the left, the red arrows indicate multiple tumors in the liver in this breast cancer patient. The CT scan on the right after allogeneic stem cell transplant shows the liver completely cleared of disease. This demonstrates the power of the GVT effect. Unfortunately, this patient later died of the GVHD side effect of this procedure.

 

SPECIALITY INFORMATION

patients


Treatment strategy designed to use the power of the human immune system to kill tumors and prevent their recurrence.
No requirement for a matched donor or chemotherapy/radiation conditioning prior to treatment.
Innovative technology – proven and non-toxic.
read more

Healthcare professionals


Therapeutic anti-tumor vaccine developed from core break-through technology called the "Mirror Effect™“ which opens a pathway to treating patients with metastatic cancer that have failed all available therapy options.
Elicits a GVT-like mechanism without the GVHD toxicity.
read more

Investors


Privately-held Israeli biopharmaceutical company spin out from Hadassah-Hebrew University Medical Center with headquarters in Jerusalem.

Over 200 individual private shareholders and grant support from the Israel Office of the Chief Scientist.
read more